NU-1025 modulates immunogenic cell death in bladder cancer: A multi-omics insight
- 1Laboratory of Urology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong Province, 524001, PR China; Corresponding authors.
- 2Department of Traditional Chinese Medicine, The Second Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong Province, 524003, PR China
- 3Laboratory of Urology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong Province, 524001, PR China
Abstract
Immune checkpoint blockade has shown limited efficacy in bladder cancer, underscoring the need for therapeutic strategies that enhance tumor immunogenicity. Immunogenic cell death (ICD) can stimulate adaptive immunity and remodel the tumor microenvironment, yet its comprehensive landscape and druggable potential in bladder cancer remain unexplored. Here, we performed integrative bioinformatics analysis of transcriptomic data from TCGA and GEO bladder cancer cohorts to characterize ICD-associated subtypes, construct a prognostic risk model, and analyze immune infiltration. Connectivity Map (CMap) database and the XSum algorithm were employed for computational drug screening. Molecular docking was used to predict interactions between candidate compounds and immune checkpoint proteins. In silico ADMET and toxicology profiles were evaluated. The clinical relevance was assessed through independent CT urography imaging and PD-L1 immunohistochemistry data. Two ICD molecular subtypes were identified with distinct prognostic and microenvironment features. An eight-gene ICD risk model was established and validated, effectively stratifying patients into high- and low-risk groups with differential survival, immune cell infiltration, and tumor mutational burden. Through computational screening, NU-1025 was nominated as a top candidate capable of reversing the high-risk gene expression pattern. In silico profiling indicated favorable drug-like properties and low toxicity risk. Clinical data analysis revealed that high-grade bladder tumors frequently exhibit low PD-L1 expression, aligning with the predicted need for ICD-inducing agents. Overall, this research decodes the ICD landscape in bladder cancer and, via a computational drug repurposing pipeline, nominates NU-1025 as a novel candidate with predicted ICD-inducing and/or immune checkpoint modulatory activity.
Related
- Mitophagy-dependent mitochondrial DNA release links ionizing radiation to immunogenic cell death in pancreatic cancer
- Antibody–drug conjugates and immunogenic cell death in breast cancer: agent-specific mechanisms, clinical evidence and translational priorities
- Prediction of prognosis and treatment effect of cervical cancer by immunogenic cell death-related genes
- COMP and CXCL10: a novel immunogenic cell death-derived gene signature for prognostic prediction in colorectal cancer
- Targeting MDA5 induces immunogenic cell death and promotes anti-tumor immunity
BibTeX
@article{li2026nu1025,
title = {{NU-1025 modulates immunogenic cell death in bladder cancer: A multi-omics insight}},
author = {Yutong Li and Ling Zuo and Xuan Dong and Ruixu Sun and Hongwei Liu},
journal = {SLAS Technology},
year = {2026},
month = oct,
doi = {10.1016/j.slast.2026.100476},
url = {https://doi.org/10.1016/j.slast.2026.100476},
note = {CC BY},
}
RIS
TY - JOUR
TI - NU-1025 modulates immunogenic cell death in bladder cancer: A multi-omics insight
AU - Yutong Li
AU - Ling Zuo
AU - Xuan Dong
AU - Ruixu Sun
AU - Hongwei Liu
PY - 2026
DA - 2026/10/30
JO - SLAS Technology
DO - 10.1016/j.slast.2026.100476
UR - https://doi.org/10.1016/j.slast.2026.100476
AB - Immune checkpoint blockade has shown limited efficacy in bladder cancer, underscoring the need for therapeutic strategies that enhance tumor immunogenicity. Immunogenic cell death (ICD) can stimulate adaptive immunity and remodel the tumor microenvironment, yet its comprehensive landscape and druggable potential in bladder cancer remain unexplored. Here, we performed integrative bioinformatics analysis of transcriptomic data from TCGA and GEO bladder cancer cohorts to characterize ICD-associated subtypes, construct a prognostic risk model, and analyze immune infiltration. Connectivity Map (CMap) database and the XSum algorithm were employed for computational drug screening. Molecular docking was used to predict interactions between candidate compounds and immune checkpoint proteins. In silico ADMET and toxicology profiles were evaluated. The clinical relevance was assessed through independent CT urography imaging and PD-L1 immunohistochemistry data. Two ICD molecular subtypes were identified with distinct prognostic and microenvironment features. An eight-gene ICD risk model was established and validated, effectively stratifying patients into high- and low-risk groups with differential survival, immune cell infiltration, and tumor mutational burden. Through computational screening, NU-1025 was nominated as a top candidate capable of reversing the high-risk gene expression pattern. In silico profiling indicated favorable drug-like properties and low toxicity risk. Clinical data analysis revealed that high-grade bladder tumors frequently exhibit low PD-L1 expression, aligning with the predicted need for ICD-inducing agents. Overall, this research decodes the ICD landscape in bladder cancer and, via a computational drug repurposing pipeline, nominates NU-1025 as a novel candidate with predicted ICD-inducing and/or immune checkpoint modulatory activity.
SN - 2472-6303
SN - 2472-6311
ER -